Novo Nordisk, the promise to shrink, and the boxes that refused

Tuesday, 3 February 2026, just after half past five in the evening, Copenhagen time: a surprise filing after the stock market had closed. Novo Nordisk, the maker of Wegovy and Ozempic, published a promise almost no company ever makes: this year, its sales would shrink. This column is about one mechanic, price times volume: sales are two numbers wearing one coat, and you will see which one moved before the room does.

Its chief executive, Mike Doustdar, called 2026 “a year of unprecedented pricing pressure”. Keep that sentence.

The next morning investors took nearly $50bn off the company's value, the most expensive way yet found of saying “noted”.

Last Wednesday I read Novo's third-quarter report, coffee in hand. The promise to shrink has now been raised for the third time: this year's sales are now expected to be roughly flat, anywhere from a little down to a little up.

So how does a company promise to shrink, and then fail? Few companies have worked this hard to miss a target. Hold on.

## Two numbers, one coat

Novo sells medicines for diabetes and obesity. In February it promised that its sales, leaving out a one-off boost, would fall by as much as 13 per cent at steady exchange rates. It blamed “lower realised prices”, the price it actually collects, including a deal with Washington to cut American prices.

Nine months later, somebody counted the boxes.

Sales are the number of things sold multiplied by the price each one fetches. Either number can carry the other: sell twice as many at half the price and the total does not move. So when sales rise or fall, ask which of the two moved first.

Novo’s own report answers it: growth was “driven by GLP-1 volume growth in both operating units, partly offset by lower realised prices”. In plain words: more boxes, cheaper boxes.

The new Wegovy pill, launched in America in January, sold about DKK 5.4bn ($800mn) in the third quarter alone. It is hard to shrink when your customers keep swallowing the forecast.

## The price half

Here is the cold part.

Turn the page after the raised outlook and Novo says it will cut the American list price of Wegovy by about half from 1 January 2027. It adds that this “is expected to impact Novo's cash flow in 2027”. It was on page 15, one page after the champagne.

In fairness, it is still a promise of roughly flat sales, not growth. Reported operating profit for the quarter fell 9 per cent after it cut the value it puts on a drug in development and on factories. Until the annual report signs it, a beaten forecast is still a forecast.

Right of reply: Novo Nordisk had not been asked for comment before publication on 9 November 2026. Any response will be added here, with the date it arrived.

Profit looks better this quarter partly because last year's restructuring, which cut about 9,000 jobs, more than half of them in Denmark, is no longer in the comparison. Those costs were people.

## The verdict

Three signals to watch: sales that hold while the price falls; a report that says which number moved; the page where next year's price is already printed.

My verdict: Novo let the payer write its forecast, building lower prices into the February promise, and the extra boxes have beaten it ever since.

Most companies show you the coat and hope you never ask what is inside. Novo printed both numbers, and the second one gets a lot cheaper in January.

“A year of unprecedented pricing pressure,” Doustdar said in February. The pressure arrived on schedule; so, it turned out, did the patients.

The list prices fall on 1 January, and the 2026 annual report will settle the promise; both are in my diary. Next in my queue: Ford, and the two cents of every dollar that went missing.

Law No. 33 · Let the Payer Write Your Forecast

Understand Business. Better.
Max Noble